CYP3A4 and rheumatoid arthritis: - plasma exposure decreased by 45% in RA patients 1 week after sarilumab injection, as compared to baseline, - one dose led to decreased of CRP level and IL-6 inhibition and, thus, restauration of CYP3A enzyme activity